GlucoTrack, Inc.
GCTKHealthcareNASDAQMedical Devices · Last scanned Sep 9, 2026
Scan Results
Daily timeframeGlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company carries a $2.3M market cap, placing it firmly in the micro-cap category. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
Market Cap
$2.3M
Beta
—
P/E (TTM)
0.17
P/E (Fwd)
—
EPS (TTM)
$17.37
EPS (Fwd)
—
ROE
-620.6%
ROA
-164.5%
Cash
$1.1M
Total Debt
$2.0M
Free CF
-$10.4M
52W Change
-95.7%
Annual Financials
Cash vs Debt
Where GCTK stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, GCTK finished 310.47% above its 150-day moving average ($0.86) and 95.03% above its 200-day moving average ($1.81). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GCTK overbought or oversold?
At the September 3, 2026 close, GCTK's RSI(14) was 82.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
GlucoTrack, Inc. carries $2.0M in total debt against $1.1M in cash reserves — debt is roughly 1.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$10.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -620.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GCTK.